Q-omics provides the consensus-scored CHCHD3P3 profile across patient tissues and cancer cell-line models. CHCHD3P3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CHCHD3P3 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, CHCHD3P3 RNA expression shows 17,942 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, LIHC, and ACC as cancer lineages where CHCHD3P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHCHD3P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHCHD3P3 survival associations across molecular data types. CHCHD3P3 RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHCHD3P3 RNA expression–survival associations across cancer types. High CHCHD3P3 expression shows unfavorable associations in MESO, CESC, LGG, BLCA and PAAD, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for CHCHD3P3 RNA expression.
This table summarizes CHCHD3P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CHCHD3P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHCHD3P3 shows higher tumor expression in LIHC, KIRP, CHOL, LUAD, LUSC and BRCA. The LIHC box plot shows higher CHCHD3P3 RNA expression in tumor versus normal tissue (log2 FC = +0.444, t-test p < 0.001).
This table shows molecular features associated with CHCHD3P3 in patient tissues and cancer cell lines. In patient samples, CHCHD3P3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
